drugset / Trial / NCT03544905
Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33
NaSingle-groupOpen-labelTreatment
Summary
This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.
Timeline
- Start
- 2018-07-05
- Primary completion
- 2024-12-04
- Completion
- 2024-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RISOVALISIB | Small molecule | 1 mg | — |
| Subject | RISOVALISIB | Small molecule | 5 mg | — |
| Subject | RISOVALISIB | Small molecule | 10 mg | — |
| Subject | RISOVALISIB | Small molecule | 20 mg | — |
| Subject | RISOVALISIB | Small molecule | 30 mg | — |
| Subject | RISOVALISIB | Small molecule | 50 mg | — |
| Subject | RISOVALISIB | Small molecule | 75 mg | — |
| Subject | RISOVALISIB | Small molecule | 100 mg | — |
| Subject | RISOVALISIB | Small molecule | 130 mg | — |
| Subject | RISOVALISIB | Small molecule | 160 mg | — |
| Subject | RISOVALISIB | Small molecule | 200 mg | — |
| Subject | RISOVALISIB | Small molecule | 240 mg | — |